Abstract
Background: In the NCI-MATCH trial, pts receive agents based on the genetic alterations in their tumors. In sub-protocol EAY131-Z1K, pts with AKT1 E17K mutant metastatic tumors received the pan-AKT inhibitor ipatasertib.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
